Andersons pediatric cardiology 155

Innovationinthepharmaceuticalindustry:New
estimatesofR&Dcosts.JHealthEcon.
2016;47:20–33.
276.AbramsJ,ConleyB,MooneyM,etal.National
CancerInstitute'sprecisionmedicineinitiatives
forthenewnationalclinicaltrialsnetwork.Am
SocClinOncolEducBook.2014;71–76.
277.JohnsonJA.Ethnicdifferencesincardiovascular
drugresponse:Potentialcontributionof
pharmacogenetics.Circulation.2008;118:1383–
1393.
278.TaylorMR,SunAY,DavisG,etal.Race,
commongeneticvariation,andtherapeutic
responsedisparitiesinheartfailure.JACCHeart
Fail.2014;2:561–572.
279.AzzimatoV,GennebackN,TabishAM,
BuyandelgerB,KnollR.Desmin,desminopathy
andthecomplexityofgenetics.JMolCell
Cardiol.2016;92:93–95.
280.BrodehlA,DiedingM,BiereN,etal.Functional
characterizationofthenovelDESmutation
p.L136Passociatedwithdilatedcardiomyopathy
revealsadominantfilamentassemblydefect.J
MolCellCardiol.2016;91:207–214.
281.LeWinterMM,GranzierH.Cardiactitin:A
multifunctionalgiant.Circulation.
2010;121:2137–2145.


282.ChauveauC,RowellJ,FerreiroA.Arisingtitan:
TTNreviewandmutationupdate.HumMutat.

2014;35:1046–1059.
283.LabeitS,GautelM,LakeyA,TrinickJ.Towards
amolecularunderstandingoftitin.EMBOJ.
1992;11:1711–1716.
284.HermanDS,LamL,TaylorMR,etal.
Truncationsoftitincausingdilated
cardiomyopathy.NEnglJMed.2012;366:619–
628.
285.HinsonJT,ChopraA,NafissiN,etal.Heart
disease.TitinmutationsiniPScellsdefine
sarcomereinsufficiencyasacauseofdilated
cardiomyopathy.Science.2015;349:982–986.
286.BarrangouR,FremauxC,DeveauH,etal.
CRISPRprovidesacquiredresistanceagainst
virusesinprokaryotes.Science.2007;315:1709–
1712.
287.IshinoY,ShinagawaH,MakinoK,AmemuraM,
NakataA.Nucleotidesequenceoftheiapgene,
responsibleforalkalinephosphataseisozyme
conversioninEscherichiacoli,andidentification
ofthegeneproduct.JBacteriol.
1987;169:5429–5433.
288.JinekM,ChylinskiK,FonfaraI,etal.A
programmabledual-RNA-guidedDNA
endonucleaseinadaptivebacterialimmunity.


Science.2012;337:816–821.
289.CarrollKJ,MakarewichCA,McAnallyJ,etal.
Amousemodelforadultcardiac-specificgene

deletionwithCRISPR/Cas9.ProcNatlAcadSci
USA.2016;113:338–343.
290.ElRefaeyM,XuL,GaoY,etal.Invivogenome
editingrestoresdystrophinexpressionand
cardiacfunctionindystrophicmice.CircRes.
2017.
291.LongC,AmoasiiL,MireaultAA,etal.Postnatal
genomeeditingpartiallyrestoresdystrophin
expressioninamousemodelofmuscular
dystrophy.Science.2016;351:400–403.
292.NelsonCE,HakimCH,OusteroutDG,etal.In
vivogenomeeditingimprovesmusclefunction
inamousemodelofDuchennemuscular
dystrophy.Science.2016;351:403–407.
293.MaH,Marti-GutierrezN,ParkSW,etal.
Correctionofapathogenicgenemutationin
humanembryos.Nature.2017.